Exscien Corp, a Mobile-based biotechnology firm that develops drugs to repair damage to mitochondrial DNA, will provide the first available treatment for diverse and common diseases, ranging from organ transplant to multi-organ system failure. The company is working on studies in the lung, stroke and cardiac model.
The Exscien team includes co-founders Christine Chancery, Steve Cumbie and Dr. Mark Gillespie and Dr. Glenn Wilson, Chief Scientific Officer.
Exscien, one of the first tenants of the University of South Alabama’s Coastal Innovation Hub, won a Phase II of the Small Business Technology Transfer National Institute of Health grant.
“Participating in the Alabama Launchpad program catalyzed Exscien’s emergence as a start-up company. The program encouraged us to think more creatively and tactically about commercializing our discovery into a new drug product, and it brought our team into contact with experts having credentials in the business side of drug development.” Mark Gillespie, Co-Founder